What is the recommended dose of dasatinib?

Dasatinib (Dasatinib) is a cancer drug that slows the growth and spread of cancer cells in the body. Dasatinib is used in adults and children to treat a type of blood cancer called Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Dasatinib is also used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) in adults and children.

The recommended dose of dasatinib varies based on the patient's specific condition and stage. The following are recommended dosages for different conditions:

Patients with chronic phase chronic myeloid leukemia (CML): The recommended starting dose is 100 mg once daily. The time of taking should be consistent, you can choose to take it in the morning or evening.

CML patients in accelerated phase and blast phase (including blast myeloblastosis and blast crisis): The recommended starting dose is 70 mg, which needs to be taken twice a day, in the morning and evening.

Dosage adjustment:

If patients fail to achieve hematological or cytogenetic remission at the recommended starting dose, patients with chronic phase CML may have their dose increased to 140 mg once daily.

For patients with CML in the progressive phase (accelerated phase and blast phase)The dose can be increased to 90 mg twice daily.

Please note that these recommended dosages are based on clinical trials and physician recommendations for standard treatment regimens, but actual dosages may be adjusted based on individual patient differences, tolerance, and other medical conditions. Therefore, before using dasatinib, patients should consult a professional physician to determine the most appropriate dose based on their individual circumstances.

In addition, it is worth emphasizing that patients should follow their doctor's instructions when taking dasatinib and have regular checkups to monitor treatment effects and possible side effects. If you have any discomfort or questions, you should consult a medical professional promptly.